Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched, including oligodendrocyte progenitor cells; strongest in bergmann glia | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 89 | 0.82 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12758
Sealed predictions
- XYLT1 in oligodendrocytes, braak-0.13 (p 0.735) → +0.00 (p 1.000)receipt 12765
- XYLT1 in dopamine neurons, braak+0.00 (p 1.000) → -0.41 (p 0.269)receipt 12766
Swarm cases
receipt 12766: XYLT1 in dopamine neurons, braak
- power
- full sample -0.10 (p 0.683, n 18), 95% CI -0.54 to +0.38. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.709, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.170, n 18). could be the mix.
- skeptic
- leave-one-out range -0.24 to +0.01, sign flips 1; without severely affected donors -0.10 (p 0.683, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for XYLT1 in dopamine neurons.
case closed: nothing better to follow up.
receipt 12765: XYLT1 in oligodendrocytes, braak
- power
- full sample -0.08 (p 0.741, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.741, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.27 (p 0.281, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to +0.03, sign flips 4; without severely affected donors -0.08 (p 0.741, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for XYLT1 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts